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Case report
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The presence ofanti-thyroid antibodies can cause artefactual estimates ofthyroid
hormones by radioimmunoassay. We describe a case of myxoedema with
spuriously high serum total and 'free' thyroxine (T4) levels which were initially
misleading. Further investigations revealed the presence of IgG autoantibodies
to T4.
CASE HISTORY
A 29-year-old male Caucasian with no relevant family history presented with a
history of constipation, increasing tiredness and a feeling of intense coldness. His
performance at sport, notably rugby and cricket, had fallen off badly largely
because of weakness and muscle stiffness. His hair was falling out and his skin
had become very dry. The clinical diagnosis was of myxoedema. He had a past
history of nocturnal convulsions related to heavy alcohol consumption for which
he was taking phenytoin sodium 100mg at night, but alcohol intake was now
modest. Initial tests of thyroid function were surprisingly high - serum total T4
124nmol/1 (reference range 60-160), serum 'free' T4 168pmol/I (reference
range 9-28). He was referred to St Luke's Hospital, Guildford, for further
investigation.
On examination he appeared myxoedematous. Heart rate was regular, 60
beats/min, and pulse was of small volume. Blood pressure was 120/80mmHg.
The thyroid gland was not enlarged. Examination of the nervous system and in
particular of the tendon reflexes produced normal results. Electromyography
suggested a mild proximal myopathy. Motor nerve conduction velocities of the
right median and lateral popliteal nerves were in the low normal range at 50 and
34 m/sec respectively; sensory action potential of the median nerve at the wrist
on stimulation of the index finger had normal amplitude of9pV but a prolonged
peak latency of 4msec. ECG showed sinus rhythm with low voltage complexes
and T-wave inversion.
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Detailed thyroid function tests are shown in the Table. Other screening investig-
ations were normal apart from serum creatine kinase 3250U/i (normal < 160)
and aspartate transaminase 129U/i (normal <40). Serum phenytoin was
<lOpmol/l. Serum albumin was 47g/l and total plasma protein 83g/l with a
normal electrophoretic pattern. Serum IgG, IgM and IgA were all within normal
limits. Haemoglobin was 11.3g/dl with normal indices and differential white cell
count and the ESR was 5mm/h. The basal metabolic rate determined by
spirometry was low at 83.9kJ/h/m2 (-45% of mean for age and sex). He was
started on triiodothyronine replacement therapy and the dose titrated to his TSH
response. He improved rapidly both symptomatically and physically. Within three
months, ECG, EMG and nerve conduction tests reverted to normal and he
reported that he had not felt so well for at least a year. BMR rose to normal
(-4%, 153kJ/h/m2).
METHODS
Serum total T4, total T3 and TSH were measured by radioimmunoassay using
polyethyleneglycol-accelerated double antibody methodsand antisera developed
in this laboratory. Serum total T4 wasalso measmd-following extraction ofserum
by an acid-ethanol method.' Serum 'free' T4 was measured by equilibrium
radioimmunoassay using a commercial kit (IM 2050) obtained from Amersham
International. Further free T4 measurements were made by equilibrium dialysis2
and by a two-step solid-phase antibody method.3
Endogenous thyroid hormone antibodies:
(i) Increasing (five-fold) dilutions of serum (50p1) were incubated with 200p1
aliquots of either iodinated T4 (800pg), T3 (10pg) or the Amersham T4
analogue (an unknown amount). After 4 hours incubation at room
temperature, aliquots (250p1) of normal carrier serum were added to the
mixture followed by an equal volume (500p1) of a 20% solution of PEG
6000. Afterthorough mixing, the immunoglobulin fraction was precipitated
by centrifugation and the associated radioactivity counted. Binding of the
tracers by the patient's serum was compared with that to normal serum
specimens.
(ii) The patient's serum was used at a 1:25 final dilution to set up a thyroxine
immunoassay standard curve using iodinated-T4 as tracer and a variable
amount of unlabelled T4 within the range 0-480nmol/l. After overnight
incubation at 4IC, bound and free labelled thyroxine were separated by the
addition of carrier serum and PEG as described above. Data was computed
by Scatchard analysis. Cross reactivity was estimated by a similar method
and by comparing the percentage ofbound tracer in the presence ofa range
of concentrations of unlabelled T4 (0-480nmol/1) or thyroglobulin
(O - 230nmol/l).
(iii) An aliquot (100p1) of the patient's serum was incubated with 4ng of T4
tracerfor 2 hours at room temperature. Asample (10p1) ofthe incubate was
subjected to separation by electrophoresis on cellulose acetate. Aliquots of
normal serum treated similarly were run in parallel. A marker strip was
stained with Ponceau Sand thesample strips.were sliced to correspond with
the marker bands. The slices were counted for radioactivity content.
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(iv) Serum was examined for T4 autoantibodies by an ELISA system. The
method uses T4-coated micro-titred plates and enzyme-labelled antihuman
IgG antibodies as the detector.4
Thyroid microsomal and thyroglobulin autoantibodies were estimated using
commercial haemagglutination kits (Wellcome Reagents Ltd, London).
TABLE
Thyroid hormone profile at presentation
Result Reference range
Total T4 (direct) 216 60 - 160nmol/l
Total T4 (extracted) < 20 60- 160nmol/1
Total T3 0.5 1.2-3.0nmol/1
Free T4 (Amerlex) 163 9-28pmol/I
Free T4 (2-step) 1
Free T4 (dialysis) 5 9- 17pmol/I
TSH-basal 160 < 5mU/lI
-20min post TRH (200pg) 205 > 10 < 40mCI/I
-60min post TRH 230 >10 <40mU/I
TBG 9.7 7-17mg/l
Anti-thyroglobulin Ab 1:320
Anti-thyroid microsomal Ab 1:10000
RESULTS
Thyroid function tests on presentation are shown in the Table. The serum total T4
by the 'in house' radioimmunoassay was moderately elevated and the serum
'free' T4 by the widely used Amerlex radioimmunoassay was very considerably
elevated into the range for severe hyperthyroidism. Nevertheless the basal serum
TSH was very high, consistent with primary hypothyroidism. The reason for the
conflict in the results is suggested by the low serum total T3, in the hypothyroid
range. The true low values for total T4 and free T4 by methods which eliminated
interfering factors ultimately confirmed that the patient had primary hypo-
thyroidism. The effect of treatment with triiodothyronine on serum TSH and
creatine kinase activity is shown in the Figure opposite.
The patient's serum bound 75.0% ofthe 1251-T4 tracer compared with only 4.1 %
binding by a control serum. It also bound 66.5% of the 1251-T4 analogue
compared with 7.5% binding by control serum. lodinated T3 was bound 13.0%
by the patient's serum and 11.2% by control serum. These tests were repeated
many times but the results remained essentially unchanged throughout the first
100 days of treatment. After electrophoresis 72.2% of the T4 tracer activity
recovered was associated with theY-globulin fraction of the patient's serum and
13.9% and 10.4% with theTBGand albumin/pre-albumin fractions respectively.
The control serum produced values of 1.0% (Y-globulin), 81.2% (TBG) and
15.2% (albumin/pre-albumin). A positive reaction in the ELISA test confirmed
the presence of T4-binding IgG.
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The effect of treatment with triiodothyronine onTSH & creatine kinase activity
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The association constant of the autoantibodies for T4 at 40C calculated by
Scatchard analysis was 1.2 x 108 litres/mole and the concentration of binding
sites 0.3umol/l. Cross reactivity of the autoantibodies with thyroglobulin was
between 200% and 900% of that with thyroxine on a molar basis, the exact
figure depending on the incubation conditions. Thyroid microsomal and thyro-
globulin autoantibodies were present in titres of 1:10,000 and 1:320 respect-
ively on presentation and had fallen to 1:640 and 1:160 respectively after three
months treatment.
DISCUSSION
Thyroid hormone-binding proteins in the -*globulin region ofthe electrophoreto-
gram were first described in a patient with papillary carcinoma of the thyroid
following radioiodine treatment.5 They have subsequently been described in
euthyroid subjects, patients with autoimmune thyroiditis, Graves' disease,
nontoxic nodular goitre and in hypothyroid patients treated with dessicated
thyroid extract6-'0 and, rarely, in nonthyroidal illness. The subject has recently
been reviewed.1' The prevalenceofthyroid hormone-binding inthyroid screening
studies has been variously described as lying within the region 0.05% 12 to 1 %.13
The antibodies are directed against T3 or T4 though sometimes both occur in the
same patient.7,9
The anomalous thyroid function tests in the present case raised our suspicion of
autoantibodies directed against one or both of the thyroid hormones. Laboratory
analyses confirmed the presence of IgG antibodies capable of binding T4 to a
degree which was sufficient to explain the spurious results. The double antibody
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separation method of RIA used in our laboratory led to a falsely high total T4.
Acid-ethanol extraction of the serum to eliminate interfering factors from the
assay system revealed a true serum total T4 concentration below the lowest
standard (<20nmol/1). Similar interference was observed with the thyroxine
analogue kit (Amerlex) which purports to measure 'free' T4. Measurement of free
T4 by such analogue methods has been the subject of much ongoing controversy
as to the soundness of the methodological precepts.14 15 Measurement of free T4
by methods not susceptible to the presence of abnormal binding proteins
revealed very low levels. The diagnosis ofprimary hypothyroidism was confirmed
by the high TSH and low total T3 levels, the response to TRH and the clinical
improvement produced by treatment with triiodothyronine.
The calculated association constant of the T4 autoantibody was low compared
with other published estimates7 8 9 16 and its binding capacity was roughly
equivalent tothatofTBG. Consequently interference in theT4 assay was relatively
slight due to only partial sequestration of the iodinated T4 used as tracer in the
assay. This resulted in an apparently normal or only mildly elevated total T4 level
thereby allaying suspicion that the analytical result was very wrong and putting
the clinical diagnosis in doubt. Antibodies of greater avidity and/or titre would
have bound virtually all the assay label recording a result ofsuch proportions that
suspicion ofits validity would have been raised immediately. Inother cases9 17 the
binding characteristics of the antithyroid hormone antibodies were such as to
suggest a definitive role for them in the development of the hypothyroid state.
Investigation ofthe autoantibody in the present case confirmed thyroglobulin as a
more specific antigen than T4. There is a marked correlation between the
presence of antithyroglobulin antibodies and antithyroid hormone antibodies8
often with preferential binding of thyroglobulin to the antithyroid hormone
antibodies16' 18 suggesting a more extensive recognition site. The absence of
(a significant titre of) antithyroglobulin antibody has, however, also been
recorded6' 18 but this may be a methodological artefact due to the presence of
haemagglutination-inhibiting factors which can occur in autoimmune thyroid
disease.19 The fact that the autoantibodies showed minimal binding to T3
suggested replacement therapy with triiodothyronine as the treatment of choice.
The resultsoftreatment onTSH and creatine kinase activity reveal theirsensitivity
to even suboptimal doses ofT3. This patient's lymphocytes have now been fused
witha mouse myelomacell line(DrKTan, DepartmentofBiochemistry, University
of Surrey, Guildford - personal communication) and the resulting hybridomas
are producing thyroxine binding antibodies.
Thiscase illustratesthe need forfurther investigation inapatientwhose symptoms
and signs do not match laboratory results and emphasises TSH measurement as
the investigation of choice for suspected primary hypotyhroidism.
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© The Ulster Medical Society, 1986.
78Thyroxine-binding autoantibodies 79
REFERENCES
1. Daughaday WL, Mariz IK, Blethen SL. Inhibition ofaccess of bound somatomedin to membrane
receptor and immunobinding sites: a comparison of radio-receptor and radioimmunoassay of
somatomedin in native and acid-ethanol extracted serum. J Clin Endocrinol Metab 1980; 51:
781-8.
2. Gow SM, Kellet HA, Toft AD, Beckett GJ. Accuracy and precision of five analog radioimmuno-
assays for free thyroxin compared. Clin Chem 1985; 31: 1888-92.
3. Ekins RP. The direct immunoassay of free (non-protein bound) hormones in body fluids. In:
Hunter WM, Corrie JET, eds. Immunoassays for clinical chemistry. Edinburgh: Churchill-
Livingstone, 1983; 319-39.
4. Goodburn R. Biochemical and clinical investigations of thyroid autoantibody antigen systems
in vitro using labelled antibody techniques. Guildford: University of Surrey, 1983. PhD thesis.
5. Robbins J, Rall JE, Rowson RW. An unusual instance of thyroxine-binding by human serum
gammaglobulin. J Clin Endocrinol Metab 1956; 16: 573-9.
6. Wu S-Y, Green WL. Triiodothyronine (T3)-binding immunoglobulins in a euthyroid woman:
effects on measurement of T3 (RIA) and on T3 turnover. J Clin Endocrinol Metab 1976; 42:
642-52.
7. Ginsberg J, Segal D, Ehrlich RM, Walfish PG. Inappropriate triiodothyronine (T3) and thyroxine
(T4) radioimmunoassay levels secondary to circulating thyroid hormone autoantibodies. Clin
Endocrinol 1978; 8: 133-9.
8. Staeheli V, Valloton MB, Burger A. Detection of human antithyroxine and anti-triiodothyronine
antibodies in different thyroid conditions. J Clin Endocrinol Metab 1975; 41: 669-75.
9. Beckett GJ, Todd JA, Hughes GJ, Campbell IW. Primary hypothyroidism with grossly elevated
plasma total thyroxine and triiodothyronine levels. Clin Endocrinol 1983; 19: 295-303.
10. Beck-Peccoz P, Romelli PB, Cattaneo MG, et al. Evaluation of free thyroxine methods in the
presence of iodothyronine-binding autoantibodies. J Clin EndocrinolMetab 1984; 58: 736-9.
11. Sakata S, Nakamura S, Miura K. Autoantibodies against thyroid hormones or iodothyronine.
Ann Int Med 1985; 103: 579-89.
12. Fielding AM. Prevalence of serum autoantibody binding of Amerlex thyroxin analog. Clin Chem
1984; 30: 501-2.
13. Mullinger RN, Walker G. Free thyroxin in thyroid disease. Clin Chem 1982; 28: 1394-5.
14. Ekins R, Jackson T. Letter. Lancet 1985; 2: 782.
15. Wilkins TA, Midgley JEM, Barron N. Comprehensive study of a thyroxin-analog-based assay
for free thyroxin ('Amerlex FT4'). Clin Chem 1985; 31: 1644-53.
16. Konishi J, lida Y, Kousaka T, Ikekubo K, Nakagawa T, Torizuka K. Effect of anti-thyroxin auto-
antibodies on radioimmunoassay of free thyroxin in serum. Clin Chem 1982; 28: 1389-91.
17. Karlsson FA, Wibell L, Wide L. Hypothyroidism due to thyroid-hormone binding antibodies.
NEnglJ Med 1977; 296: 1146.8.
18. Pearce CJ, Byfield PGH, Edmonds CJ, Lalloz MRA, Himsworth RL. Autoantibodies to thyro-
globulin cross-reacting with iodothyronines. Clin Endocrinol 1981; 15: 1-10.
19. Wilkin TJ, Swanson BeckJ, HayesPC, Potts RC, Young RJ. A passive haemagglutination (TRC)
inhibitor in thyrotoxic serum. Clin Endocrinol 1979; 10: 507-14.
© The Ulster Medical Society, 1986.